Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 175

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 175
---
HOLDERS’ EQUITY:Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding— — Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 40,554,705 and 31,841,084 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively4 3 Additional paid-in capital1,140,328 713,636 Accumulated deficit(568,779)(381,426)Total stockholders’ equity 571,553 332,213 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $615,886 $370,025 

See notes to consolidated financial statements.

F-4

KEROS THERAPEUTICS, INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

YEAR ENDED DECEMBER 31,202420232022REVENUE:Service and other revenue$550 $151 $— License revenue3,000 — — Total revenue3,550 151 — OPERATING EXPENSES:Research and development(173,629)(135,258)(87,265)General and administrative(40,754)(34,834)(27,525)Total operating expenses(214,383)(170,092)(114,790)LOSS FROM OPERATIONS(210,833)(169,941)(114,790)OTHER INCOME (EXPENSE), NET:Interest expense, net— — (1)Research and development incentive income1,238 2,400 7,081 Dividend income23,496 14,755 3,644 Other expense, net(954)(206)(613)Total other income (expense), net23,780 16,949 10,111 Loss before income taxes(187,053)(152,992)(104,679)Income tax provision(300)— — Net loss$(187,353)$(152,992)$(104,679)Net loss attributable to common stockholders—basic and diluted$(187,353)$(152,992)$(104,679)